Immunogen fails to leap Forward
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
Boston bid for BTG shows dreams can come true
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Fireworks among the small and mid-cap device makers
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.